StreetInsider.com News Articles

Haemonetics (HAE) PT Raised to $85 at Mizuho

Mon, 15 Jun 2026 06:39:41 -0400

(Updated - June 15, 2026 6:39 AM EDT)

Mizuho analyst Anthony Petrone raised the price target on Haemonetics (NYSE: HAE) to $85.00 (from $70.00) while maintaining a Outperform rating.

The analyst commented: "We have been fielding consistent in-bounds on HAE (OP) out-performance since mid-May, as shares have surged +46% vs +3.5% for the S&P 500 over that time. We credit the strong rebound in shares over the past several weeks to evidence that the end-market for intravenous immunoglobulin (Ig) products (the key driver to the company's plasma-collection business) remains healthy coupled with its NexSys system still performing better than competition in the

Haemonetics (HAE) PT Raised to $85 at Mizuho

Mon, 15 Jun 2026 06:39:41 -0400

(Updated - June 15, 2026 6:39 AM EDT)

Mizuho analyst Anthony Petrone raised the price target on Haemonetics (NYSE: HAE) to $85.00 (from $70.00) while maintaining a Outperform rating.

Form ARS HAEMONETICS CORP For: Mar 28

Tue, 09 Jun 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260609/26624012.html

Form ARS HAEMONETICS CORP For: Mar 28

Tue, 09 Jun 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260609/26624012.html

Form DEFA14A HAEMONETICS CORP

Tue, 09 Jun 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260609/26623961.html

Form DEFA14A HAEMONETICS CORP

Tue, 09 Jun 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260609/26623961.html

Form DEF 14A HAEMONETICS CORP For: Mar 28

Tue, 09 Jun 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260609/26623921.html

Form DEF 14A HAEMONETICS CORP For: Mar 28

Tue, 09 Jun 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260609/26623921.html

Form 4 HAEMONETICS CORP For: Jun 05 Filed by: Maunsell Farris Maryanne

Mon, 08 Jun 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260608/26617620.html

Form 4 HAEMONETICS CORP For: Jun 05 Filed by: Maunsell Farris Maryanne

Mon, 08 Jun 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260608/26617620.html

Form 4 HAEMONETICS CORP For: Jun 05 Filed by: Miller Laurie A.

Mon, 08 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260608/26617563.html

Form 4 HAEMONETICS CORP For: Jun 05 Filed by: Miller Laurie A.

Mon, 08 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260608/26617563.html

Form 8-K HAEMONETICS CORP For: Jun 05

Fri, 05 Jun 2026 06:33:00 -0400

si-local-file:///var/storage/secattach/20260605/26608158.html

Form 8-K HAEMONETICS CORP For: Jun 05

Fri, 05 Jun 2026 06:33:00 -0400

si-local-file:///var/storage/secattach/20260605/26608158.html

Haemonetics restructures reporting segments from three to two

Fri, 05 Jun 2026 06:30:51 -0400

Haemonetics Corporation (NYSE: HAE) announced it will restructure its financial reporting segments, transitioning from three reportable segments to two effective with its first quarter fiscal 2027 results.

The medical technology company will combine its previously separate Plasma and Blood Center segments into a single Apheresis segment. The Hospital segment will be renamed MedSurg. The company stated the updated segment names better reflect the underlying businesses, technologies, and markets served.

The new reporting structure will begin with the first quarter of fiscal year 2027, which commenced on March 29, 2026. Haemonetics will continue providing supplemental revenue disclosure within each segment. The Apheresis segment

Haemonetics Updates Financial Reporting Segments